title: Fibronectin-based scaffold domain proteins that bind myostatin: a patent evaluation of WO2014043344.
abstract: Muscular dystrophies (MD) are commonly characterized by progressive loss of muscle mass and function. It is hypothesized that therapeutic blockade of the TGF-β ligand myostatin, a negative regulator of muscle mass, will stimulate muscle growth and restore muscle function. Although many anti-myostatin targets are currently being pursued in the clinical setting, the efficacies of the tested molecules have shown mixed results. The patent WO2014043344 describes a novel approach for myostatin inhibition using a modified fibronectin type III domain that could potentially be used to treat MD and other muscle-related pathologies.
authors: University of Cincinnati, College of Medicine, Department of Molecular Genetics, Biochemistry and Microbiology , Cincinnati, OH, 45267 , USA.
authors: Ryan G
authors: RG
authors: Walker
authors: Thomas B
authors: TB
authors: Thompson
mesh_terms: D000818:Animals; D018450:Disease Progression; D015195:Drug Design; D005353:Fibronectins / Q000378:metabolism*; D006801:Humans; D058990:Molecular Targeted Therapy; D009135:Muscular Diseases / Q000188:drug therapy / Q000503:physiopathology; D009136:Muscular Dystrophies / Q000188:drug therapy* / Q000503:physiopathology; D055435:Myostatin / Q000037:antagonists & inhibitors*; D010330:Patents as Topic
chemical_list: D005353:Fibronectins; D055435:Myostatin
keywords: TGF-β; biological therapies; fibronectin; growth and differentiation factor-8; muscle wasting; muscular dystrophy; myostatin